Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - pramipexoldihydrokloridmonohydrat - depottablett - 2,62 mg - pramipexoldihydrokloridmonohydrat 3,75 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - pramipexoldihydrokloridmonohydrat - depottablett - 1,05 mg - pramipexoldihydrokloridmonohydrat 1,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - pramipexoldihydrokloridmonohydrat - depottablett - 2,1 mg - pramipexoldihydrokloridmonohydrat 3 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

animedica gmbh - bensylpenicillinprokainmonohydrat - intramammär suspension - 3 g - bensylpenicillinprokainmonohydrat 3 g aktiv substans; propylenglykol hjälpämne - nöt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

chanelle pharmaceuticals manufacturing ltd - moxidektin - oral lösning - 1 mg/ml - moxidektin 1 mg aktiv substans; propylenglykol hjälpämne; bensylalkohol hjälpämne - får

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

vetviva richter gmbh - azaperon - injektionsvätska, lösning - 40 mg/ml - azaperon 40 mg aktiv substans; natriummetabisulfit hjälpämne; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne - svin

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.